2013 Biotech & Standards Conference Participant: Brad A. Margus

Brad A. Margus
CEO, Genome Bridge

Brad A. Margus is the Chief Executive Officer of Genome Bridge, a new non-profit organization working with world-class partners to build an unparalleled technology for aggregating genomic and clinical data to improve medicine.  In this role, Margus draws on his experiences as an entrepreneur and advocate, building and leading diverse teams striving to improve medicine.

In 1993, Margus – a Harvard MBA working in the food processing industry – learned that two of his sons had an ultra-rare, lethal genetic disease that combined a loss of muscle control with cancer and immune deficiency. While still running his company, he studied molecular genetics, formed a non-profit, raised over $30 million through nationwide grassroots efforts bringing in 140,000 donations, organized scientific conferences, funded research projects worldwide, created tissue banks, established a clinic at Johns Hopkins Hospital, and coordinated clinical trials. He also advocated for other genetic disorders, frequently testifying before Congress and appearing in the national media.

In 2000, Margus left the food industry to start Perlegen Sciences as CEO. Perlegen raised $257 million from investors without using agents and became a leader in analyzing genetic variation, discovering diagnostic markers for disease risk as well as adverse drug effects.

In late 2009, Margus raised $8 million from investors and started Envoy Therapeutics as CEO to identify proteins selectively expressed in the circuitry of brain diseases and to advance compounds acting on those proteins toward the clinic. Three years later, in October 2012, Margus sold Envoy to Takeda Pharmaceuticals for $140 million.

Margus has been a member of numerous IRBs, NIH advisory committees and corporate boards. He has served on the Advisory Council to the National Institute of Neurological Disorders and Stroke at the NIH; the Secretary of Health and Human Services’ Advisory Committee on Genetics, Health and Society; the Board of the Genetic Alliance, an umbrella organization representing hundreds of genetic disease advocacy organizations; the Board of Children’s Neurobiological Solutions, an organization aimed at applying brain repair and regeneration to pediatric neurological disorders; and on the Stanford University School of Medicine’s Stem Cell Research Oversight Committee.

He currently serves as Chairman and volunteer President of the A-T Children’s Project; as a Harvard Business School Global Advisor; as an advisor to the Rare Disease Network; on the Board of Second Genome, a microbiome company; and as Co-chair of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) External Oversight Board.